Twentyeight-Seven Therapeutics is focused on the modulation of functional non-coding RNA (ncRNA) to treat cancer and other human diseases. By targeting ncRNA modulating proteins (RMPs), we can use small molecules to modulate expression levels of oncogenes and other proteins of significance in disease.

The company’s core technology comes from its four founding scientists, all leading researchers in RNA biology and cancer from Harvard Medical School.